Press release

Akili Grows Leadership Team with Chief Financial Officer and General Counsel Appointments

Sponsored by Businesswire

Akili Interactive (“Akili”), a leading digital medicine company creating
prescription treatments for people living with cognitive dysfunction,
today announced the addition of two new executives to the Akili
leadership team. Santosh Shanbhag has been named Chief Financial Officer
and Jacqueline Studer has been named Senior Vice President and General
Counsel of Akili.

This press release features multimedia. View the full release here:

Jackie Studer, SVP & General Counsel, Akili (Photo: Business Wire)

Jackie Studer, SVP & General Counsel, Akili (Photo: Business Wire)

“Santosh and Jackie are talented executives whose extensive business
strategy and diverse industry experience make them the perfect fit for
our growing business,” said Eddie Martucci, CEO of Akili. “They bring
tremendous financial and legal expertise to the company which will help
us continue to challenge the status quo of medicine on our path to
deliver new hope to patients living with cognitive dysfunction.”

Shanbhag is a senior financial executive with 20 years of experience
leading financial operations for U.S. and international organizations
and executing complex business programs for transformative healthcare
companies. Prior to joining Akili, Shanbhag held senior finance
leadership roles at Vertex Pharmaceuticals, most recently as Vice
President and Head of International Finance and Accounting where he
helped build-out the international business and secure reimbursement for
novel medicines in key international markets. Prior to Vertex, Shanbhag
served in positions of increasing responsibility at Capgemini Consulting
and Texas Instruments. He holds an M.S. in Management & Engineering from
MIT and Sloan School of Management, and an M.S. in Mechanical
Engineering from the University of Massachusetts, Amherst.

“I’m excited to be an Akilian and look forward to helping the company
scale and globalize its business as Akili delivers on its promise to
redefine medicine and the healthcare experience,” said Shanbhag.

Studer has decades of experience providing legal strategy and support to
large and emerging growth healthcare companies. Prior to joining Akili,
she served as Corporate Vice President, General Counsel and Secretary at
IDEXX Laboratories, where she led the legal, compliance and regulatory
organizations and was charged with building a legal, privacy and
regulatory organization and framework to support the company’s rapid
global expansion. She held prior roles leading the legal, privacy and
compliance organizations at Blue Health Intelligence, Allscripts
Healthcare Solutions, and various leadership positions at GE Healthcare
including as General Counsel of the GE Healthcare IT & Performance
Solutions division. Studer holds a bachelor’s degree in management from
Purdue University and a J.D. from Columbia University School of Law.

“With its engaging technology and ground-breaking science, Akili has a
unique opportunity to personalize the treatment of cognitive
dysfunction,” said Studer. “I am honored to be a part of the Akili team
as we work to change how patients interact with their medicine company.”

About Akili
Akili is a leading digital medicine company
combining scientific and clinical rigor with the ingenuity of the tech
industry to reinvent medicine. Akili is pioneering the development of
prescription digital treatments with direct therapeutic activity,
delivered not through a pill but through a high-quality action video
game experience. Akili is advancing a broad pipeline of programs to
treat cognitive deficiency and improve symptoms associated with medical
conditions across neurology and psychiatry, including
attention-deficit/hyperactivity disorder, major depressive disorder,
autism spectrum disorder and various inflammatory diseases. The Company
is also developing complementary and integrated clinical monitors and
measurement-based care applications. Akili was co-founded by PureTech
(PRTC.L) and is a founding member of the Digital
Therapeutics Alliance
. For more information on Akili, please visit:

Forward Looking Statement
This press release contains
statements that are or may be forward-looking statements, including
statements that relate to the company’s future prospects, developments
and strategies. The forward-looking statements are based on current
expectations and are subject to known and unknown risks and
uncertainties that could cause actual results, performance and
achievements to differ materially from current expectations. These
statements are not guarantees of future performance and undue reliance
should not be placed on them. These forward-looking statements are based
on assumptions regarding the present and future business strategies of
the company and the environment in which it will operate in the future.
Each forward-looking statement speaks only as at the date of this press
release. Except as required by law and regulatory requirements, neither
the company nor any other party intends to, and expressly disclaims any
obligation to, update or revise these forward-looking statements,
whether as a result of new information, future events or otherwise.